ライフサイエンスコーパス: left ventricular mass

1 ied as scar percentage (infarcted mass/total left ventricular mass).

2 secondary objective was to assess changes in left ventricular mass.

3 organ damage as measured by albuminuria and left ventricular mass.

4 abetes, and had larger left atria and higher left ventricular mass.

5 graphic PR interval, atrial fibrillation and left ventricular mass.

6 ardiac magnetic resonance imaging-determined left ventricular mass.

7 mber dilation and a compensatory increase in left ventricular mass.

8 bjects (13%; P<0.0001) with no difference in left ventricular mass.

9 as 39% (SD 12) and scar occupied 24% (10) of left ventricular mass.

10 age, sex, hypertension, body mass index, and left ventricular mass.

11 septum (62%), despite a greater increase in left ventricular mass.

12 (ACE-I) results in substantial reduction in left ventricular mass.

13 into account age and a morphometric index of left ventricular mass.

14 lated to the ratio of lumen area to regional left ventricular mass.

15 ranch lengths were used to estimate regional left ventricular mass.

16 systolic and diastolic blood pressures, and left ventricular mass.

17 oprotein concentrations, blood pressure, and left ventricular mass.

18 n concentrations, blood pressure levels, and left ventricular mass.

19 ion in septal thickness and 17% reduction in left ventricular mass.

20 lity using various methods of indexation for left ventricular mass.

21 h incident cardiovascular disease and higher left ventricular mass.

22 % (interquartile range: 1.3% to 4.1%) of the left ventricular mass.

23 fat compartment is strongly correlated with left ventricular mass.

24 f body composition and fat distribution, and left ventricular mass.

25 s of wave reflection are not associated with left ventricular mass.

26 organ damage as measured by albuminuria and left ventricular mass.

27 n=4 per group, p<0.02) resulting in greater left-ventricular mass (1.24 [0.29] vs 1.57 [0.27] g) and

28 ure (diastolic dimension [1.5%, P=0.008] and left ventricular mass [1.6%, P=0.008]), resting stroke v

29 lumes (96 versus 40 mL), and greater indexed left ventricular mass (101 versus 85 g/m(2); P<0.01 for

30 A significant reduction in left ventricular mass (118+/-24 g vs. 101+/-18 g) and ca

31 tone resulted in significant improvements in left ventricular mass (-14 +/- 13 g vs. +3 +/- 11 g, p <

32 t failure were more likely to have increased left ventricular mass (17.0 percent vs. 26.9 percent), l

33 ll thickness (0.83 and 0.78 versus 0.72 cm), left ventricular mass (182 and 161 versus 137 g), and re

34 L-NAME induced hypertrophy (weight-indexed left-ventricular mass 2.2+/-0.3 versus 4.1+/-0.4 mug/g,

35 short-axis cine images were used to quantify left ventricular mass, 3-dimensional geometric variation

36 (7.1+/-1.2 versus 5.1+/-1.1 cm; P<0.001) and left ventricular mass (320+/-113 versus 194+/-79 g; P<0.

37 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m(2) reduction; padjusted =

38 Individuals born preterm had increased left ventricular mass (66.5+/-10.9 versus 55.4+/-11.4 g/

39 g alcohol intake was associated with greater left ventricular mass (8.2+/-3.8 g per consumption categ

40 entricular posterior wall, 11+/-4 [7-21] mm; left ventricular mass, 86+/-41 [46-195] g/m(2)) was prog

41 s associated with an estimated 2.4-g greater left ventricular mass (95% confidence interval, 0.4-4.5

42 l body weight had fallen by 3% (P<0.05), but left ventricular mass, adjusted for changes in body surf

43 tricular weight, right ventricle weight, and left ventricular mass after 4 months of VD deficiency.

44 operated mice showed significantly increased left ventricular mass after 7 days.

45 influence of these factors on changes in the left ventricular mass after renal transplantation.

46 cid and renal dysfunction, on changes in the left ventricular mass after renal transplantation.

47 videnced by greater left atrial diameter and left ventricular mass although diastolic dysfunction was

48 ngiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-st

49 Exercise training increased left ventricular mass and blood volume by approximately

50 There was no significant correlation between left ventricular mass and BP either at HBPM or ABPM.

51 There was no significant correlation between left ventricular mass and BP either at HBPM or ABPM.

52 White coat normotension is associated with left ventricular mass and carotid wall thickness similar

53 loss of diurnal BP variation; (d) increased left ventricular mass and cavity dimensions; (e) decreas

54 Left ventricular mass and CK metabolite levels in LVH we

55 spontaneously hypertensive rats, it reduced left ventricular mass and collagen content, reduced prot

56 ary composite outcomes of death or change in left ventricular mass and death or change in self-report

57 extracellular volume (r=0.72; P<0.01), with left ventricular mass and E' velocity (r=0.45, -0.60, re

58 To examine left ventricular mass and evaluate factors associated wi

59 he differential effects of various agents on left ventricular mass and events.

60 Contrast-to-noise ratios (CNRs) and left ventricular mass and function measurements with thi

61 Both SUR1-tg and Kir6.2 KO mice had normal left ventricular mass and function under unstressed cond

62 ay partly explain the ability of high normal left ventricular mass and high normal clinic blood press

63 worse CAD, lower ejection fraction, greater left ventricular mass and higher C-reactive protein valu

64 over time was associated with an increase in left ventricular mass and higher mortality.

65 dy demonstrates that allopurinol can regress left ventricular mass and improve endothelial function a

66 The use of spironolactone reduces left ventricular mass and improves arterial stiffness in

67 Left ventricular mass and LA size were independently ass

68 atients with diabetes mellitus had a greater left ventricular mass and left atrial area than patients

69 ty, body mass index (BMI), serum creatinine, left ventricular mass and left ventricular ejection frac

70 End diastolic volume, end systolic volume, left ventricular mass and left ventricular ejection frac

71 over time was associated with a decrease in left ventricular mass and lower mortality, whereas a dec

72 Left ventricular mass and myocyte size were similar in t

73 Quantitative ECG measures of left ventricular mass and repolarization predict outcome

74 Indexed left ventricular mass and right ventricular mass (left v

75 ationship was evident between LGE by percent left ventricular mass and SCD event risk in HCM patients

76 of patients from both groups, we reassessed left ventricular mass and self-reported physical health

77 C-EV injection also resulted in reduction in left ventricular mass and superior perfusion in the infa

78 le factors may contribute to lower levels of left ventricular mass and volume.

79 resonance images for assessment of right and left ventricular mass and volumes were obtained at basel

80 owed that treatment with losartan normalized left ventricular mass and wall thickness.

81 n analyses found an inverse relation between left ventricular mass and weight z score (r = -0.45, P =

82 here were no significant differences between left ventricular masses and systemic pressures, and ther

83 e heart, such as increased left atrial size, left ventricular mass, and alterations in transmitral ve

84 We measured body fat distribution, left ventricular mass, and blood pressure at the age of

85 Age, left ventricular mass, and body surface area were the ma

86 usted for age, race/ethnicity, hypertension, left ventricular mass, and end-diastolic volume.

87 and relative wall thicknesses, chamber size, left ventricular mass, and end-systolic wall stress.

88 assical Fabry disease had lower eGFR, higher left ventricular mass, and higher plasma globotriaosylsp

89 measured global longitudinal strain, indexed left ventricular mass, and indexed left atrial volume.

90 adjusted for baseline left atrial dimension, left ventricular mass, and left ventricular fractional s

91 rt failure as measured by ejection fraction, left ventricular mass, and lung congestion.

92 Measures of left atrial size, left ventricular mass, and peak A velocity at baseline w

93 ischemic region was 40.1+/-3.1% of the total left ventricular mass, and the infarct size was 47.5+/-3

94 adjustment for age, gender, body mass index, left ventricular mass, and traditional risk factors.

95 apeutic efficacy, such as ejection fraction, left ventricular mass, and ventricular volume, can be de

96 -1.5); 1.30 (1.15-1.48) per 1 SD increase in left ventricular mass; and 1.15 (1.02-1.30) per 1 SD inc

97 brachial pulse and systolic blood pressure, left ventricular mass, aortic wall thickness and mean ao

98 Heart weight and left ventricular mass are elevated, and histology reveal

99 ess and system inflammation and reduction of left ventricular mass are less robust.

100 The primary endpoint was change in left ventricular mass as assessed by cardiac magnetic re

101 Echocardiography showed increases in left ventricular mass as well as end-diastolic and end-s

102 n (3.2+/-1.8%, 6.7+/-4.4%, and 9.9+/-3.2% of left ventricular mass at 2, 6, and 48 hours, respectivel

103 re paravalvular leak at 30 days, and greater left ventricular mass at 30 days.

104 less valve, there were similar reductions in left ventricular mass at 6 months with both stented and

105 0.001) and a doubling (or more) of risk with left ventricular mass at the mean value or lower (P for

106 Hypoenhanced areas (as a percentage of left ventricular mass) at first-pass multidetector CT (1

107 in FVC from peak was associated with larger left ventricular mass (beta = 6.05 g per SD of FVC decli

108 d no significant difference in the change in left ventricular mass between the placebo group and the

109 Pairs were matched for age, gender, indexed left ventricular mass, body mass index and low-density l

110 ent fractional shortening (2=.5, P<.01), and left ventricular mass/body surface area (r2=.5, P<.001)

111 ventricular mass and right ventricular mass (left ventricular mass/body surface area, 96+/-13 and 62+

112 lograft hypertrophy, we measured the gain in left ventricular mass by 2D echocardiography in heart tr

113 tid intima-media thickness, ankle-arm index, left ventricular mass by ECG, and a major ECG abnormalit

114 The MESA measured left ventricular mass by MRI, coronary calcium by comput

115 ly acquired and later analyzed for right and left ventricular mass by radial summation technique from

116 roalbuminuria was positively associated with left ventricular mass (by 14.8 g), leading to a signific

117 entricular end-diastolic volume (LVEDV), and left ventricular mass (by echocardiography) at rest, dur

118 (bioimpedance spectroscopy), 24-hour BP, and left ventricular mass (cardiac magnetic resonance imagin

119 Left ventricular mass (cardiac magnetic resonance) and a

120 Whether the differences in left-ventricular mass changes are related to endogenous

121 and known genetic variants predict increased left ventricular mass, circulating levels of NT-proBNP,

122 ersus 20 of 64 [31%]; P<0.001) and change in left ventricular mass correlated with intraseason change

123 Consequently, an increase in left ventricular mass corresponding to exaggerated wall

124 LV left ventricular wall thinning with LV left ventricular mass decrease occurred at follow-up (S0

125 Left ventricular mass, distal left anterior descending c

126 abnormal results on perfusion scans (<10% of left ventricular mass) during stress (n = 136), a preser

127 ar filtration rate (isotopic clearance), and left ventricular mass (echocardiography) assessment were

128 c use, estimated glomerular filtration rate, left ventricular mass, ejection fraction, and wall motio

129 ificantly lower adjusted mean values for the left ventricular mass, end diastolic volume, and stroke

130 FMM could be estimated from left ventricular mass (FMM = 0.46 + 0.002 x mass, r = 0.

131 It ranged from approximately 8 g shift in left ventricular mass for 10p13 locus heterozygosity for

132 gy and developed normal values for right and left ventricular mass from 15 weeks' gestation to term.

133 o 114 424 +/- 9564 nuclei/mm3, P < 0.01) and left ventricular mass (from 2.5 +/- 0.1 to 2.8 +/- 0.1 g

134 ts born preterm have distinct differences in left ventricular mass, function, and geometry.

135 gender, cardiovascular (CV) disease, EF, and left ventricular mass, grade II DD was associated with a

136 CMR-LVH was defined as left ventricular mass >/=95th percentile of the MESA pop

137 udinal strain (>15% improvement) and indexed left ventricular mass (>20% decrease) at 1 year occurred

138 Left ventricular mass had high reliability and little re

139 ensional echocardiography for measurement of left ventricular mass has high accuracy and low variabil

140 rp step-up was observed for scar size >5% of left ventricular mass (hazard ratio [HR]: 5.2; 95% confi

141 uretic peptide, ejection fraction, E/E', and left ventricular mass (hazard ratio: 1.164; 95% confiden

142 essure, height and fat distribution; and for left ventricular mass, height, race, sex, and fat distri

143 Infarct size was assessed as percent left ventricular mass hyperenhanced 5 to 10 minutes afte

144 y arterial hypertension (PAH), and increased left ventricular mass (ILVM) in antiretroviral therapy (

145 Individuals born preterm have increased left ventricular mass in adult life.

146 Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted a

147 Increasing left ventricular mass in athlete's heart occurs because

148 acteristics demonstrate the association with left ventricular mass in healthy non-obese population.

149 receptor blockers are effective in reducing left ventricular mass in hypertension and heart failure.

150 ssion of carotid IMT and greater decrease in left ventricular mass in individuals with type 2 diabete

151 skin sodium content to be closely linked to left ventricular mass in patients with CKD.

152 has been found to accelerate the increase in left ventricular mass in patients with hypertension.

153 consortium) and rs198389 and rs3733402 with left ventricular mass in whites (EchoGEN consortium).

154 differences in cardiac size, the changes in left-ventricular mass in response to age and hypertrophi

155 od pressure, a high-salt diet also increases left ventricular mass, incidence of strokes, stiffness o

156 r: a difference which becomes more marked as left ventricular mass increases.

157 Whereas left-ventricular mass increases with age in apparently h

158 P < .001); and there was greater decrease in left ventricular mass index (-2.4 g/m(2.7) vs -1.2 g/m(2

159 ypertension did not differ significantly for left ventricular mass index (4 g/m2 [CI, - 3 to 10 g/m2)

160 were independently associated with increased left ventricular mass index (5% increase per 1-SD increa

161 rcise-induced wall motion abnormalities, and left ventricular mass index (beta=-0.41 [95% confidence

162 ion fraction, stroke volume index, E/E', and left ventricular mass index (hazard ratio, 4.1; 95% conf

163 fraction (HR, 0.42; 95% CI, 0.20-0.89), and left ventricular mass index (HR, 1.19; 95% CI, 1.04-1.36

164 lization (OR, 9.36; 95% CI, 2.55-34.38), and left ventricular mass index (in g/m(2)) (OR, 1.02; 95% C

165 standard (135-140/85-90 mmHg) BP control on left ventricular mass index (LVMI) and kidney function i

166 he relationship between hematocrit (Hct) and left ventricular mass index (LVMI) and LV hypertrophy (L

167 d larger left atrial (LA) volumes and higher left ventricular mass index (LVMI) and LV mass/LV volume

168 Left ventricular mass index (LVMI) correlated to the sam

169 The primary outcome was change in left ventricular mass index (LVMI) measured by transthor

170 led trial evaluated the effect of EVL on the left ventricular mass index (LVMi) of 30 nondiabetic RTR

171 and obese hypertensive patients had greater left ventricular mass index (LVMI) values, but on multiv

172 ssure (SBP), heart rate (HR), pathology, and left ventricular mass index (LVMI) were measured.

173 We measured left ventricular mass index (LVMI) with cardiac magnetic

174 aphy and pulsed Doppler were used to measure left ventricular mass index (LVMI), cardiac index (CI),

175 line and 12-mo measures of echocardiographic left ventricular mass index (LVMI), serum C-reactive pro

176 and after 12 months there was a reduction in left ventricular mass index (p < 0.03).

177 id not significantly differ in the change in left ventricular mass index (P = 0.37), left ventricular

178 correlation with O2max (r=-0.53, P=0.003 and left ventricular mass index (r=-0.44, P=0.02).

179 Increased left ventricular mass index alone did not affect accurac

180 rams and computed tomography scans to assess left ventricular mass index and coronary artery calcific

181 late human aging: age-dependent increases in left ventricular mass index and left atrial dimension, w

182 Left ventricular mass index and left atrial volume index

183 FGF-23 is independently associated with left ventricular mass index and left ventricular hypertr

184 Left ventricular mass index and relative wall thickness

185 Prespecified end points included left ventricular mass index and, in a subpopulation of p

186 Spironolactone induced reverse remodeling (left ventricular mass index declined; difference, -6 g/m

187 During the study, LVH prevalence and mean left ventricular mass index did not change significantly

188 At 48 weeks, the change in left ventricular mass index did not differ between treat

189 Left ventricular mass index fell to 75% of the preoperat

190 The mean change in left ventricular mass index from randomization was simil

191 The left ventricular mass index had good discrimination for

192 Predictors of left ventricular mass index included systolic BP, anemia

193 The median left ventricular mass index measured with echocardiograp

194 Moreover, this increase in left ventricular mass index occurs in children who have

195 on fraction of 65.5%+/-12.0% and a mean+/-SD left ventricular mass index of 66.6+/-22.3 g/m(2.7) Duri

196 week therapy with paricalcitol did not alter left ventricular mass index or improve certain measures

197 tricted to the CKD subjects (11% increase in left ventricular mass index per 1-SD increase in log FGF

198 Left ventricular mass index tended to decrease, whereas

199 as a continuous measure, an increase in any left ventricular mass index was associated with similar

200 g the subset of participants with ALVSD, the left ventricular mass index was particularly informative

201 In bivariate analyses, age, left ventricular mass index, and DD grade were positivel

202 re, cholesterol, smoking, ejection fraction, left ventricular mass index, and diabetes mellitus-the e

203 nemia, sodium intake, income, fat-free mass, left ventricular mass index, and ejection fraction.

204 e in serum uric acid during follow-up, final left ventricular mass index, and final glomerular filtra

205 ted with greater disease severity, a greater left ventricular mass index, and higher hospitalization

206 ng 20 or 40mg/kg/day showed a decline in the left ventricular mass index, compared to an increase in

207 ion fraction, but individual adjustments for left ventricular mass index, left atrial area, and inter

208 ressure, left ventricular ejection fraction, left ventricular mass index, left ventricular dimension,

209 Secondary end points were changes in left ventricular mass index, left ventricular ejection f

210 ) had more severe aortic stenosis, increased left ventricular mass index, more myocardial injury (hig

211 medication use, glomerular filtration rate, left ventricular mass index, wall motion abnormalities,

212 model was used to assess the effect of BP on left ventricular mass index, which was measured at three

213 agreement among the ECG criteria against the left ventricular mass index.

214 improved, with no evidence of an increase in left ventricular mass index.

215 volume but also with significantly increased left ventricular mass index.

216 Echocardiography was used to estimate the left ventricular mass index.

217 orrelation between ventricular CT-1 mRNA and left ventricular mass index.

218 nt and significant determinants of the final left ventricular mass index.

219 The left-ventricular-mass index decreased more in the low-bl

220 The left-ventricular-mass index decreased significantly from

221 the estimated GFR, a greater decline in the left-ventricular-mass index, and greater reduction in ur

222 Left ventricular mass indexed according to height at the

223 er, in vivo MRI showed only a 3% increase in left ventricular mass indexed for body weight in mice wi

224 Various left ventricular mass indexes (e.g., mass indexed for he

225 ventricular systolic dysfunction, as well as left ventricular mass, internal dimensions, and wall thi

226 ans, we identified 4 genetic loci related to left ventricular mass, interventricular septal wall thic

227 Left ventricular mass is a risk factor for cardiovascula

228 Left ventricular mass is known to be a powerful independ

229 Increased left-ventricular mass is an important cardiovascular ris

230 sus 64%; P=0.99) and the proportion of total left ventricular mass (%late gadolinium enhancement; 10.

231 7 kdyne/cm2; P < .0002) and greater relative left ventricular mass (left ventricular weight [g]/body

232 nce and severity of coronary artery disease, left ventricular mass, left ventricular ejection fractio

233 ith further adjustment for physical fitness, left ventricular mass, left ventricular ejection fractio

234 Peak filling rate correlated with fat mass, left ventricular mass, leptin, waist-to-hip ratio, and p

235 ents scanned by MRI and SPECT was 14+/-6% of left ventricular mass (%LV) by MRI (range 4%LV to 27%LV)

236 scular obstruction (MO) in the percentage of left ventricular mass (%LV) was assessed by cardiac magn

237 Left ventricular mass (LVM) and cardiac gene expression

238 ren, cardiac abnormalities such as increased left ventricular mass (LVM) and diastolic dysfunction de

239 ver, information on the relationship between left ventricular mass (LVM) in adults and longitudinal m

240 ascertain if high-dose allopurinol regresses left ventricular mass (LVM) in patients with ischemic he

241 r high-dose allopurinol causes regression of left ventricular mass (LVM) in patients with type 2 diab

242 eatment resulted in a sustained reduction in left ventricular mass (LVM) index after 5 years (from 71

243 Left ventricular mass (LVM) is a highly heritable trait

244 his study was to determine whether increased left ventricular mass (LVM) is a risk factor for the dev

245 An increase in left ventricular mass (LVM) is associated with mortality

246 Left ventricular mass (LVM) is correlated with body comp

247 of ischemic stroke associated with increased left ventricular mass (LVM) is modified by physical acti

248 We assessed left ventricular mass (LVM) regression with transthoraci

249 R and determine the relative contribution of left ventricular mass (LVM) regression, change in aortic

250 f age, serum phosphate, pulse wave velocity, left ventricular mass (LVM), and LVM index (LVMI) increa

251 cardiovascular magnetic resonance to measure left ventricular mass (LVM), and PET to quantify resting

252 Left ventricular mass (LVM), left ventricular (LV) geome

253 t significantly associated with AS gradient, left ventricular mass, mass/volume ratio, or ejection fr

254 reductions in left ventricular dilation and left ventricular mass measured echocardiographically in

255 dependent of subclinical atherosclerosis and left ventricular mass measures.

256 Left ventricular mass (median [25th, 75th percentiles],

257 ether with preprocedural hospitalization and left ventricular mass, myocardial injury is an independe

258 ller increase in heart-to-body weight ratio, left ventricular mass, myocyte cross-sectional area, hyp

259 ge left ventricular end-diastolic volume and left ventricular mass nor did it improve submaximal exer

260 median changes (95% confidence intervals) in left ventricular mass of -0.84 (-17.1 to 10.0) g and 1.4

261 y end point was microvascular obstruction (% left ventricular mass) on cardiac magnetic resonance ima

262 use, lipid levels, progression to diabetes, left ventricular mass or function, and kidney disease.

263 nd systolic blood pressure, and with a lower left ventricular mass (P values<0.05).

264 idase inhibition-positive men showed greater left ventricular mass (P=0.02) and substantially lower r

265 revascularization, 12.6% (7.2% to 22.6%) of left ventricular mass, p = 0.57 (95% confidence interval

266 dian [interquartile range], 7.0 [4.9-7.5]; % left ventricular mass) peaked on day 2 (P<0.001), wherea

267 VEGF treatment preserved left ventricular mass, prevented dilation (T: 1.01+/-0.0

268 rdiovascular magnetic resonance (eg, indexed left ventricular mass R=0.56, P<0.001).

269 0.23), systolic blood pressure (r=0.26), and left ventricular mass (r=0.37).

270 ongly than total body overhydration did with left ventricular mass (r=0.56, P<0.001 versus r=0.35, P<

271 ve tissue volume fraction and weight-indexed left-ventricular mass (r=0.842 and r=0.737, respectively

272 was 2.0 g (range, 0.7 to 12.2 g), or 1.5% of left ventricular mass (range, 0.4% to 6.0%).

273 d pressure, left ventricular wall thickness, left ventricular mass, ratio of heart weight to tibial l

274 lities, including left ventricular dilation, left ventricular mass reduction, and depression of fract

275 Left ventricular mass remained constant in all race/gend

276 nce: rs4552931 in UBE2V2 (P=1.43x10(-7)) for left ventricular mass, rs7213314 in WIPI1 (P=1.68x10(-7)

277 r TAC, CARP-ssARKct hearts had elevations in left ventricular mass similar to those in NLCs; however,

278 ypertrophy, defined by different indexes for left ventricular mass, similarly confers increased risk

279 P =.001; patients: +8 mL [6%], P =.001) and left ventricular mass smaller (healthy subjects: -25 g (

280 ts regarding the optimal method for indexing left ventricular mass to body size in the clinical setti

281 sulted in a greater increase in the ratio of left ventricular mass to chamber volume and a better pre

282 positively related to the ratio of elevated left ventricular mass to end-diastolic volume (0.02 g/mL

283 , leading to a significantly higher ratio of left ventricular mass to end-diastolic volume (by 8%).

284 entric remodeling determined by the ratio of left ventricular mass to end-diastolic volume (M/V ratio

285 content is a strong explanatory variable for left ventricular mass, unaffected by BP and total body o

286 Left-ventricular mass, wall thickness; myocyte size, myo

287 The gain in left ventricular mass was 73% in heart transplant recipi

288 ynamics was measured by Pulse Wave Analysis, left ventricular mass was assessed by echocardiography,

289 Left ventricular mass was determined by the M-mode ("Pen

290 After adjustment for confounders, the mean left ventricular mass was found to be 26 gm lower in pat

291 For every 1% higher glycated hemoglobin, left ventricular mass was higher by 3.0 g (95% confidenc

292 -/-)ApoB(100/100) mice with aortic stenosis, left ventricular mass was increased by 67% (P=0.001) and

293 Left ventricular mass was increased, consistent with gen

294 n (36% vs. 3%), and age- and gender-adjusted left ventricular mass was lower (90 +/- 27 g/m vs. 117 g

295 Posterior wall thickness and left ventricular mass were also increased, but dimension

296 d systemic vascular resistance and increased left ventricular mass were also noted.

297 0 mL; P=0.09) without significant changes in left ventricular mass were observed.

298 Increased vascular resistance and left ventricular mass were the most consistent findings

299 Regression of left ventricular mass with nocturnal hemodialysis has be

300 ng dysglycemia was associated with increased left ventricular mass, worse diastolic function, and sub